These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644 [TBL] [Abstract][Full Text] [Related]
6. Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis. Matsukawa A; Rajwa P; Kawada T; Bekku K; Laukhtina E; Klemm J; Pradere B; Mori K; Karakiewicz PI; Kimura T; Chlosta P; Shariat SF; Yanagisawa T Int J Clin Oncol; 2024 Jun; 29(6):716-725. PubMed ID: 38582807 [TBL] [Abstract][Full Text] [Related]
7. Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis. Mori K; Mostafaei H; Sari Motlagh R; Pradere B; Quhal F; Laukhtina E; Schuettfort VM; Kramer G; Abufaraj M; Karakiewicz PI; Kimura T; Egawa S; Shariat SF BJU Int; 2022 Apr; 129(4):423-433. PubMed ID: 34171173 [TBL] [Abstract][Full Text] [Related]
8. The optimal upfront therapy in metastatic hormone-sensitive prostate cancer: A network meta-analysis. Mutlu H; Bozcuk H J Cancer Res Ther; 2023; 19(2):394-402. PubMed ID: 37313915 [TBL] [Abstract][Full Text] [Related]
9. Systemic therapies for high-volume metastatic hormone-sensitive prostate cancer: a network meta-analysis. Zhou Z; Liu S; Mei J; Liu T; Liu F; Zhang G Acta Oncol; 2023 Sep; 62(9):1083-1090. PubMed ID: 37548225 [TBL] [Abstract][Full Text] [Related]
10. Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis. Sathianathen NJ; Koschel S; Thangasamy IA; Teh J; Alghazo O; Butcher G; Howard H; Kapoor J; Lawrentschuk N; Siva S; Azad A; Tran B; Bolton D; Murphy DG Eur Urol; 2020 Mar; 77(3):365-372. PubMed ID: 31679970 [TBL] [Abstract][Full Text] [Related]
11. Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis. Roy S; Sayyid R; Saad F; Sun Y; Lajkosz K; Ong M; Klaassen Z; Malone S; Spratt DE; Wallis CJD; Morgan SC Eur Urol Oncol; 2022 Oct; 5(5):494-502. PubMed ID: 35811293 [TBL] [Abstract][Full Text] [Related]
12. Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis. Fallara G; Robesti D; Nocera L; Raggi D; Marandino L; Belladelli F; Montorsi F; Malavaud B; Ploussard G; Necchi A; Martini A Cancer Treat Rev; 2022 Nov; 110():102441. PubMed ID: 35939976 [TBL] [Abstract][Full Text] [Related]
13. [Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer]. Wenzel M; Hoeh B; Chun FKH; Mandel P Urologie; 2023 Apr; 62(4):360-368. PubMed ID: 36763112 [TBL] [Abstract][Full Text] [Related]
14. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis. Feyerabend S; Saad F; Li T; Ito T; Diels J; Van Sanden S; De Porre P; Roiz J; Abogunrin S; Koufopoulou M; Fizazi K Eur J Cancer; 2018 Nov; 103():78-87. PubMed ID: 30218976 [TBL] [Abstract][Full Text] [Related]
15. Combination therapy for high-volume Jian T; Zhan Y; Yu Y; Yu K; Hu R; Wang J; Lu J Front Pharmacol; 2023; 14():1148021. PubMed ID: 37153773 [No Abstract] [Full Text] [Related]
16. Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy. Yanagisawa T; Hata K; Narita S; Hatakeyama S; Mori K; Yata Y; Sano T; Otsuka T; Hara S; Miyajima K; Enei Y; Fukuokaya W; Nakazono M; Matsukawa A; Miki J; Habuchi T; Ohyama C; Shariat SF; Kimura T Prostate; 2023 May; 83(6):563-571. PubMed ID: 36661102 [TBL] [Abstract][Full Text] [Related]
17. Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy. Kassem L; Shohdy KS; Abdel-Rahman O Curr Med Res Opin; 2018 May; 34(5):903-910. PubMed ID: 29490505 [TBL] [Abstract][Full Text] [Related]
18. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis. Wallis CJD; Klaassen Z; Bhindi B; Goldberg H; Chandrasekar T; Farrell AM; Boorjian SA; Kulkarni GS; Karnes RJ; Satkunasivam R Eur Urol; 2018 Jun; 73(6):834-844. PubMed ID: 29037513 [TBL] [Abstract][Full Text] [Related]
19. Network meta-analysis of combination strategies in metastatic hormone-sensitive prostate cancer. Wang SS; Bian XJ; Wu JL; Wang BH; Zhang S; Ye DW Asian J Androl; 2024 Jul; 26(4):402-408. PubMed ID: 38624195 [TBL] [Abstract][Full Text] [Related]
20. Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Maiorano BA; De Giorgi U; Roviello G; Messina C; Altavilla A; Cattrini C; Mennitto A; Maiello E; Di Maio M ESMO Open; 2022 Oct; 7(5):100575. PubMed ID: 36152486 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]